UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41242 ZIMVIE INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 87-2007795 | | --- | --- | | (State or other ...

Exhibit 99.1 ZimVie Reports Second Quarter 2025 Financial Results PALM BEACH GARDENS, Florida, July 30, 2025 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter reflect the strength of our people and their unwavering commitment to executing our strategy and delivering for our customers and stakeholders," said Vafa Jamali, Chairman of the Board and Chief Execu ...

Core Viewpoint - ZimVie Inc. reported its financial results for the second quarter of 2025, showing a slight decline in net sales but an improvement in net loss compared to the previous year. The company is also in the process of being acquired by an affiliate of ARCHIMED for $19.00 per share, which will take ZimVie private and remove its shares from NASDAQ trading. Financial Performance - Net sales for Q2 2025 were $116.7 million, a decrease of 0.1% on a reported basis and 2.1% in constant currency compared to Q2 2024 [2][3] - The net loss for Q2 2025 was $(3.8) million, an improvement of $5.7 million from a net loss of $(9.6) million in Q2 2024 [3][9] - The net loss margin for Q2 2025 was (3.3%), improving by 490 basis points from (8.2%) in Q2 2024 [3][4] - Adjusted net income for Q2 2025 was $7.2 million, an increase of $3.6 million from Q2 2024 [3][4] Earnings Per Share - Basic and diluted EPS for Q2 2025 were $(0.14), while adjusted diluted EPS was $0.26 [4][9] Adjusted EBITDA - Adjusted EBITDA for Q2 2025 was $17.5 million, representing 15.0% of net sales, an increase of $1.6 million or 150 basis points from Q2 2024 [4][9] Acquisition Details - On July 21, 2025, ZimVie announced a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 in cash per share [6][7] - The transaction is expected to close by year-end 2025, pending stockholder approval and regulatory approvals [7][9] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering products for dental tooth replacement and restoration [9][10]

PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie’s entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”) for $19.00 ...

Core Insights - ZimVie Inc. has entered a strategic distribution agreement with Osstem Implant Co., Ltd. to enhance its presence in the growing Chinese dental implant market, which is estimated to exceed 10 million units annually [1][2] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [5] - Osstem Implant, founded in 1997, is the largest dental implant manufacturer globally and a leading provider in the Asia-Pacific region, with a strong distribution network in over 90 countries [6] Market Dynamics - The partnership allows ZimVie to leverage Osstem's established distribution channels and clinical training programs, enhancing customer access to ZimVie's innovative implant portfolio [2][4] - Osstem Implant has built a robust presence in over 90 cities in China and conducts nearly 500 clinical training sessions annually, which strengthens its market position [2] Strategic Benefits - The collaboration is expected to provide a wider product selection for dental professionals and patients, enhancing the overall customer experience [4] - ZimVie's premium implants are designed for precision, aesthetics, and durability, aligning with the company's commitment to innovation and global expansion [4]

Core Viewpoint - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of iTeos Therapeutics, Inc. and ZimVie Inc. [1][2] Group 1: iTeos Therapeutics, Inc. - iTeos Therapeutics, Inc. is set to be acquired by Concentra Biosciences, LLC for $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the disposition of certain product candidates within six months post-closing [1] Group 2: ZimVie Inc. - ZimVie Inc. is being sold to an affiliate of ARCHIMED for $19.00 in cash per share [2] Group 3: Legal Actions and Shareholder Rights - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4]

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating ZimVie Inc. (NASDAQ: ZIMV) related to its sale to an affiliate of ARCHIMED. Under the terms of the proposed transaction, ZimVie sha ...

Core Viewpoint - The Ademi Firm is investigating ZimVie for potential breaches of fiduciary duty and other legal violations related to its transaction with ARCHIMED, which involves a cash offer of $19.00 per share, totaling approximately $730 million in enterprise value [1][2]. Group 1 - ZimVie shareholders are set to receive $19.00 per share in cash, equating to an enterprise value of around $730 million [2]. - The transaction agreement includes provisions that significantly limit competing offers for ZimVie, imposing penalties if a competing bid is accepted [3]. - The investigation focuses on whether the ZimVie board of directors is adequately fulfilling their fiduciary responsibilities to all shareholders amidst these arrangements [3].

PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries. Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock outstanding at the cl ...

Author of the Macro Trends & Inflection Points Newsletter. I spent 5 years as a co-founder and hedge fund CIO / manager. Before that, I was a hedge fund analyst/portfolio manager at a leading Canadian alternative asset manager. I write articles as part of my own due diligence on the stocks that I find interesting.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this ...